Monthly Prescribing Reference

Aripiprazole 2-Month Under Review for Schizophrenia, Bipolar I Disorder

The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot. The Food and Drug Administration (FDA) ...
Business Wire

ABILIFY® (aripiprazole) Supplemental New Drug Application For Pediatric Patients With Schizophrenia Accepted For Priority Review By The U.S. Food And Drug Administration

TOKYO & PRINCETON, N.J.-- (BUSINESS WIRE)--Otsuka Pharmaceutical Co, Ltd., and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted ...
Healthline

All About Abilify Asimtufii

Abilify Asimtufii (aripiprazole) is prescribed to help treat schizophrenia and bipolar I disorder. The drug comes as a suspension (a liquid mixture) that a healthcare professional injects into a ...
Healthline

Abilify Overview

Abilify (aripiprazole) is a prescription drug used to treat schizophrenia and other mental health conditions. Abilify comes as a tablet that you swallow. Abilify contains the active ingredient ...